Acrivon Therapeutics, Inc. Common Stock
General ticker "ACRV" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $152.7M (TTM average)
Acrivon Therapeutics, Inc. Common Stock does not follow the US Stock Market performance with the rate: -1.1%.
Estimated limits based on current volatility of 5.2%: low 2.18$, high 2.42$
Factors to consider:
- Total employees count: 41 as of 2022
- Current price 47.9% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.15$, 10.74$]
- 2025-12-31 to 2026-12-31 estimated range: [3.57$, 9.45$]
Financial Metrics affecting the ACRV estimates:
- Negative: with PPE of -2.6 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -3.11 <= 0.33
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
- Positive: -4.48 < Investing cash flow per share per price, % of -2.45
Short-term ACRV quotes
Long-term ACRV plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $32.66MM | $67.24MM | $89.20MM |
| Operating Income | $-32.66MM | $-67.24MM | $-89.20MM |
| Non-Operating Income | $1.49MM | $6.85MM | $8.64MM |
| R&D Expense | $23.95MM | $45.49MM | $63.99MM |
| Income(Loss) | $-31.17MM | $-60.39MM | $-80.56MM |
| Profit(Loss)* | $-31.17MM | $-60.39MM | $-80.56MM |
| Stockholders Equity | $170.47MM | $121.19MM | $176.79MM |
| Assets | $181.23MM | $138.26MM | $196.59MM |
| Operating Cash Flow | $-30.12MM | $-42.64MM | $-65.67MM |
| Capital expenditure | $2.17MM | $1.29MM | $2.77MM |
| Investing Cash Flow | $-141.68MM | $50.72MM | $-51.77MM |
| Financing Cash Flow | $101.71MM | $-1.55MM | $121.03MM |
| Earnings Per Share** | $-1.42 | $-2.74 | $-2.10 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.